IL17A and metabolic dysfunction-associated steatohepatitis: IL-17-producing Treg has also been demonstrated to involve in the progression of nephrotoxic nephritis (NTN), type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH).